INCB 123667
Alternative Names: INCB-123667Latest Information Update: 09 Sep 2025
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I Solid tumours
Most Recent Events
- 09 Sep 2025 Efficacy and adverse events data from phase-I trial in Solid presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 05 Sep 2025 INCB 123667 is still in phase I trial for Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, France, Italy, Japan, the Netherlands, Puerto Rico, Switzerland, and the United Kingdom (PO, Tablet)
- 28 Aug 2025 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater) in Puerto Rico (PO) (NCT07023627)